Senator John Boozman (Republican-Arkansas) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on July 13th, the Senator disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on June 4th.
Senator John Boozman also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of abrdn Physical Palladium Shares ETF (NYSEARCA:PALL) on 6/25/2026.
- Purchased $1,001 – $15,000 in shares of iShares Expanded Tech-Software Sector ETF (BATS:IGV) on 6/25/2026.
- Sold $1,001 – $15,000 in shares of First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) on 6/25/2026.
- Sold $1,001 – $15,000 in shares of (NYSE:TPYP) on 6/25/2026.
- Sold $1,001 – $15,000 in shares of iShares 7-10 Year Treasury Bond ETF (NASDAQ:IEF) on 6/17/2026.
- Sold $1,001 – $15,000 in shares of Atmos Energy (NYSE:ATO) on 6/12/2026.
- Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 6/4/2026.
- Purchased $1,001 – $15,000 in shares of iShares CMBS ETF (NYSEARCA:CMBS) on 5/27/2026.
- Purchased $1,001 – $15,000 in shares of iShares MBS ETF (NASDAQ:MBB) on 5/27/2026.
- Purchased $1,001 – $15,000 in shares of iShares Agency Bond ETF (NYSEARCA:AGZ) on 5/27/2026.
Boston Scientific Stock Down 1.5%
Shares of NYSE BSX opened at $43.95 on Friday. The stock has a market capitalization of $65.33 billion, a PE ratio of 18.39, a P/E/G ratio of 0.84 and a beta of 0.58. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm has a fifty day moving average of $48.18 and a 200-day moving average of $65.87. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.
Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
Insider Transactions at Boston Scientific
In other news, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.
Institutional Investors Weigh In On Boston Scientific
Several hedge funds and other institutional investors have recently bought and sold shares of the business. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth about $26,000. Bangor Savings Bank increased its position in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Boston Scientific in the 4th quarter valued at about $29,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
BSX has been the topic of several research analyst reports. Jefferies Financial Group reduced their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Bank of America dropped their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Barclays cut their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Mizuho decreased their price objective on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Stifel Nicolaus dropped their price objective on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.84.
Read Our Latest Research Report on BSX
About Senator Boozman
John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Further Reading
- Five stocks we like better than Boston Scientific
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
